Please assess the completion status of the following clinical trial:

Trial Title: A RCT to Compare the Effects of Two Wound Products on Biofilm Disruption in DFUs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient is able to understand the study and is willing to consent to the study.~2. The patient consents to the ongoing use of their de-identified photos by the Sponsor for purposes outside of this study.~3. The patient must be at least 18 years of age.~4. Males and females - provided they are not pregnant or lactating and if of reproductive age are using contraception.~5. The patient has presented with a DFU which, according to the clinical judgement of the Investigator, has a suspected biofilm~6. The patient has a DFU of Grade 1 or 2 according to the Meggit-Wagner scale. Grade 1 - Superficial ulcers limited to the dermis Grade 2 - Ulcers are transdermal with exposed bone or tendon, and without osteomyelitis or abscess formation~7. The patient's ulcer is suitable to be dressed with IODOSORB or SOLOSITE.~8. The patient has an ABPI \>0.49; or toe pressure \>50mmHg.~Exclusion Criteria:~1. Patients with a known history of poor compliance with medical treatment.~2. Patients who have participated in this study previously and who healed or were withdrawn.~3. Patients who are participating in any other clinical study.~4. Patients that have received continuous treatment with Iodosorb (on any wound) in the past 8 weeks (Iodosorb must not be continuously used for more 3 months) or whose reference ulcer has been treated with Iodosorb in the past 2 weeks.~5. Patients with a history of any thyroid disorders, e.g. Hashimoto's thyroiditis, Graves disease or non-toxic nodular goitre.~6. Patients undergoing treatment with mercurial antiseptics, taurolidine or lithium.~7. Patients with a known sensitivity to iodine or any of the other ingredients in IODOSORB, SOLOSITE or ALLEVYN Non-adhesive~8. Patients with severe renal impairment~9. Patients with an ulcer less than 3cm diameter.~10. Patients with an ulcer that is not exuding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Solosite gel (Type: PLACEBO_COMPARATOR): Hydrogel with preservatives, used to create a moist wound environment.
- Iodosorb (Type: ACTIVE_COMPARATOR): Cadexomer iodine gel

Based on this trial design, predict the completion outcome and termination type (if applicable).